K. Nam

581 total citations · 1 hit paper
9 papers, 377 citations indexed

About

K. Nam is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, K. Nam has authored 9 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 7 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in K. Nam's work include Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Research and Treatments (2 papers). K. Nam is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Research and Treatments (2 papers). K. Nam collaborates with scholars based in United States, Netherlands and Canada. K. Nam's co-authors include Yves Fradet, Dean F. Bajorin, Ronald de Wit, Tara L. Frenkl, Joaquim Bellmunt, Daniel P. Petrylak, Toni K. Choueiri, David I. Quinn, David J. Vaughn and Andrea Necchi and has published in prestigious journals such as Annals of Oncology, European Urology Supplements and European Urology Open Science.

In The Last Decade

K. Nam

8 papers receiving 375 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2019 306 citations Yves Fradet, Joaquim Bellmunt et al. Annals of Oncology profile →

Peers

K. Nam

SURGE

ONCOL

PRM

IMMUN

MB

J L Lee South Korea

Radhika Walling United States

Nick van Dijk Netherlands

Urbano Anido Herranz Spain

Yao Yu United States

Akinori Minato Japan

Benjamin Miron United States

Sally Hanna Canada

Petter Kollberg Sweden

Zhisong He China

J L Lee South Korea

K. Nam

231 ×0.8

SURGE

235 ×0.9

ONCOL

82 ×0.9

PRM

27 ×1.0

IMMUN

34 ×1.4

MB

Citations per year, relative to K. Nam K. Nam (= 1×) peers J L Lee

Countries citing papers authored by K. Nam

Since Specialization

Citations

This map shows the geographic impact of K. Nam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Nam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Nam more than expected).

Fields of papers citing papers by K. Nam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Nam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Nam. The network helps show where K. Nam may publish in the future.

Co-authorship network of co-authors of K. Nam

This figure shows the co-authorship network connecting the top 25 collaborators of K. Nam. A scholar is included among the top collaborators of K. Nam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Nam. K. Nam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Alistar, Angela, Devalingam Mahalingam, Minal Barve, et al.. (2023). 712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose. Annals of Oncology. 34. S492–S492.

2.

Alva, Ajjai, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2020). LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology. 31. S1155–S1155. 47 indexed citations

3.

Boormans, Joost L., Ronald de Wit, Edward Uchio, et al.. (2020). Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). European Urology Open Science. 19. e1173–e1174. 2 indexed citations

4.

Galsky, Matthew D., Andrea Necchi, Neal D. Shore, et al.. (2019). KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). Annals of Oncology. 30. v401–v401. 1 indexed citations

5.

Fradet, Yves, Joaquim Bellmunt, David J. Vaughn, et al.. (2019). Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of Oncology. 30(6). 970–976. 306 indexed citations breakdown →

6.

Boormans, Joost L., Arjun Vasant Balar, Ronald de Wit, et al.. (2019). Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study. European Urology Supplements. 18(1). e758–e759. 1 indexed citations

7.

Necchi, Andrea, Yves Fradet, Joaquim Bellmunt, et al.. (2019). Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). Annals of Oncology. 30. v366–v367. 9 indexed citations

8.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2018). Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial. Annals of Oncology. 29. viii304–viii304. 9 indexed citations

9.

Wit, Ronald de, Ashish M. Kamat, Joaquim Bellmunt, et al.. (2016). Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study. Annals of Oncology. 27. vi294–vi294. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact